Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024.
Key highlights from this period include:
- GMP production run initiated during the quarter, and successfully completed in April with product characterisation and quality verification on track for completion in Q2 CY2024;
- Positive preclinical data highlights the potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international workshop;
- Cash and short-term investment balance of $3 million on 31 March 2024.
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said:
“The GMP manufacturing run for PAT-DX1 started during the quarter and subsequent to the end of the quarter has recently been successfully completed. The Company expects the additional product characterisation and specification testing will be completed by Q2 CY2024. We were also pleased to announce that after the end of the quarter positive preclinical data concerning deoxymabs in animal models of the autoimmune disease vasculitis was presented during the plenary session at a leading international workshop. This potentially opens up a new therapeutic area for Patrys to develop or partner its deoxymab technology.”